Shahsavari R, Ehsani-Zonouz A, Houshmand M, Salehnia A, Ahangari G, Firoozrai M
Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Hemmat Highway, Tehran, Iran.
Pak J Biol Sci. 2009 Jan 15;12(2):140-5. doi: 10.3923/pjbs.2009.140.145.
This study was to evaluate the effect of the wild SKEO on activities and genes expression of hepatic Glycogen Phosphorylase (GP) and phosphoenolpyruvate carboxykinase (PEPCK) in normal and diabetic rats. The wild SKEO was orally administered at different doses (50 and 100 mg/kg/day) to normal as well as diabetic rats for 21 days. The levels of mRNA were determined using the quantitative real-time RT-PCR technique. The plasma glucose concentrations of diabetic rats receiving SKEO (100 mg kg(-1)) compared with diabetic control were significantly decreased. Hepatic GP activity and its mRNA levels of diabetic rats treated with SKEO moderately increased. The activity of hepatic PEPCK and its mRNA levels were significantly decreased in normal rats treated with SKEO (100 mg kg(-1)). The enhancement of PEPCK activity and its mRNA levels of diabetic treated rats with SEKO (100 mg kg(-1)) was significantly decreased compared with diabetic control. In conclusion, an excessive inhibition of PEPCK in liver of diabetic rats treated with the wild SKEO may contribute to the plasma glucose lowering action of SKEO that seems to be in relation with antioxidant properties of SKEO.
本研究旨在评估野生匙羹藤提取物(SKEO)对正常和糖尿病大鼠肝脏糖原磷酸化酶(GP)及磷酸烯醇式丙酮酸羧激酶(PEPCK)活性和基因表达的影响。将野生SKEO以不同剂量(50和100毫克/千克/天)口服给予正常及糖尿病大鼠,持续21天。使用定量实时逆转录聚合酶链反应(RT-PCR)技术测定mRNA水平。与糖尿病对照组相比,接受SKEO(100毫克/千克)治疗的糖尿病大鼠的血浆葡萄糖浓度显著降低。接受SKEO治疗的糖尿病大鼠肝脏GP活性及其mRNA水平适度增加。用SKEO(100毫克/千克)治疗的正常大鼠肝脏PEPCK活性及其mRNA水平显著降低。与糖尿病对照组相比,用SEKO(100毫克/千克)治疗的糖尿病大鼠的PEPCK活性及其mRNA水平的增强显著降低。总之,野生SKEO治疗的糖尿病大鼠肝脏中PEPCK的过度抑制可能有助于SKEO的降血糖作用,这似乎与SKEO的抗氧化特性有关。